Inhibrx Valuation
| INBX Stock | USD 15.45 0.18 1.15% |
At this time, the firm appears to be undervalued. Inhibrx retains a regular Real Value of $22.68 per share. The prevalent price of the firm is $15.45. Our model calculates the value of Inhibrx from evaluating the firm fundamentals such as Shares Outstanding of 14.48 M, return on asset of -0.57, and Return On Equity of -20.31 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Inhibrx's valuation include:
Price Book 1.2532 | Enterprise Value 29.2 M | Enterprise Value Ebitda 0.0169 | Price Sales 134.1187 | Trailing PE 0.1294 |
Undervalued
Today
Please note that Inhibrx's price fluctuation is not too volatile at this time. Calculation of the real value of Inhibrx is based on 3 months time horizon. Increasing Inhibrx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Inhibrx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Inhibrx Stock. However, Inhibrx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.45 | Real 22.68 | Target 46.75 | Hype 15.61 |
The intrinsic value of Inhibrx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Inhibrx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Inhibrx helps investors to forecast how Inhibrx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inhibrx more accurately as focusing exclusively on Inhibrx's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inhibrx's intrinsic value based on its ongoing forecasts of Inhibrx's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inhibrx's closest peers.
Inhibrx Cash |
|
Inhibrx Valuation Trend
Analysing the historical paterns of Inhibrx's enterprise value and its market capitalization is a good way to estimate and gauge the value of Inhibrx over time and is usually enough for investors to make rational market timing decisions.
Inhibrx Total Value Analysis
Inhibrx is currently forecasted to have valuation of 29.16 M with market capitalization of 226.26 M, debt of 210.14 M, and cash on hands of 176.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Inhibrx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.16 M | 226.26 M | 210.14 M | 176.38 M |
Inhibrx Investor Information
About 24.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inhibrx recorded earning per share (EPS) of 120.78. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Inhibrx's financial statements, Inhibrx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Inhibrx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inhibrx has an asset utilization ratio of 0.58 percent. This suggests that the Company is making $0.005846 for each dollar of assets. An increasing asset utilization means that Inhibrx is more efficient with each dollar of assets it utilizes for everyday operations.Inhibrx Ownership Allocation
The market capitalization of Inhibrx is $226.26 Million. Over half of Inhibrx's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Inhibrx Profitability Analysis
The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M).About Inhibrx Valuation
Our relative valuation model uses a comparative analysis of Inhibrx. We calculate exposure to Inhibrx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Inhibrx's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 609 K | 639.5 K | |
| Pretax Profit Margin | (133.18) | (126.52) | |
| Operating Profit Margin | (121.79) | (115.70) | |
| Net Loss | (134.09) | (127.38) | |
| Gross Profit Margin | 0.34 | 0.36 |
Inhibrx Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 47.1 M |
Inhibrx Current Valuation Indicators
Valuation refers to the process of determining the present value of Inhibrx and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Inhibrx we look at many different elements of the entity such as Inhibrx's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inhibrx, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inhibrx's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inhibrx's worth.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.